Celsion Corporation (CLSN)

[Rawnoc]

July 11, 2011 535 patients reviewed, 190 progression-free survival events
http://investor.celsion.com/releasedetail.cfm?ReleaseID=590333

Nov 28 2011: 613 patients reviewed, 219 progression-free survival events
http://investor.celsion.com/releasedetail.cfm?ReleaseID=627024

July 11: 345 patients with no events
Nov 28: 29 patients had events

29 out of 345 had events or 8.4% in 4.5 months. Hundreds of the patients had already been in the trial for well over a year. The event rate should have been at least double what it was bare minimum.

I must be doing something wrong. Because think about what that means if the event-rate was supposed to be double but it was cut in half in a population where half received ThermoDox.